We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
226
Paloma Partners
Connecticut
-$368K -20,000 Closed
FC
227
FIC Capital
New York
-$324K -17,600 Closed
FCBT
228
First Citizens Bank & Trust
North Carolina
-$320K -17,398 Closed
PAM
229
Paradigm Asset Management
New York
-$310K -16,850 Closed
FCH
230
Freestone Capital Holdings
Washington
-$373K -15,400 Closed
Natixis Advisors
231
Natixis Advisors
Massachusetts
-$272K -14,787 Closed
HSBC Holdings
232
HSBC Holdings
United Kingdom
-$264K -14,334 Closed
WAM
233
World Asset Management
Michigan
-$256K -13,932 Closed
PI
234
Placemark Investments
Illinois
-$234K -12,793 Closed
B
235
Baird
Wisconsin
-$235K -12,762 Closed
PM
236
Parametrica Management
Hong Kong
-$234K -12,727 Closed
AA
237
ALPS Advisors
Colorado
-$233K -12,640 Closed
AWCI
238
Alpine Woods Capital Investors
New York
-$230K -12,500 Closed
SGH
239
Schonfeld Group Holdings
New York
-$217K -11,800 Closed
PCM
240
Prelude Capital Management
New York
-$62.3K -11,537 Closed
Truist Financial
241
Truist Financial
North Carolina
-$193K -10,493 Closed
DADC
242
D.A. Davidson & Co
Montana
-$42.3K -7,826 -99%
Baillie Gifford & Co
243
Baillie Gifford & Co
United Kingdom
-$98K -5,327 Closed
BRWA
244
B. Riley Wealth Advisors
Florida
-$92K -5,000 Closed
PAM
245
Panagora Asset Management
Massachusetts
-$51K -2,771 Closed
Fifth Third Bancorp
246
Fifth Third Bancorp
Ohio
-$25K -1,340 Closed
HPBT
247
High Point Bank & Trust
North Carolina
-$22K -1,175 Closed
MFS
248
MSI Financial Services
Massachusetts
-$2.69K -498 -100%
Bessemer Group
249
Bessemer Group
New Jersey
-$5K -269 Closed
HR
250
Howe & Rusling
New York
-$4K -196 Closed

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.